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Abstract
Duchenne muscular dystrophy (DMD) is a dystrophin-deficient lethal muscle disease. To date, the 
catastrophic muscle wasting phenotype has only been seen in dystrophin-deficient humans and 
dogs. While Duchenne-like symptoms have been observed in more than a dozen dog breeds, the 
mutation is often not known and research colonies are rarely established. Here we report an 
independent canine DMD model originally derived from the Pembroke Welsh corgi breed. The 
affected dogs presented clinical signs of muscular dystrophy. Immunostaining revealed the 
absence of dystrophin and up-regulation of utrophin. Histopathologic examination showed 
variable fiber size, central nucleation, calcification, fibrosis, neutrophil and macrophage 
infiltration and cardiac focal vacuolar degeneration. Carrier dogs also displayed mild myopathy. 
The mutation was identified as a long interspersed repetitive element-1 (LINE-1) insertion in 
intron 13 which introduced a new exon containing an in-frame stop codon. Similar mutations have 
been seen in human patients. A colony was generated by crossing carrier females with normal 
males. Affected puppies had a normal birth weight but they experienced a striking growth delay in 
the first 5 days. In summary, the new corgi DMD model offers an excellent opportunity to study 
DMD pathogenesis and to develop novel therapies.
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Duchenne muscular dystrophy (DMD) results from mutations in the dystrophin gene (1). 
DMD is the most common childhood lethal muscle disease with a prevalence of 1.3 to 2.63 
per 10,000 male births (2–5). In normal striated muscle, dystrophin localizes at the cytosolic 
side of the sarcolemma. It protects the sarcolemma from contraction-associated shearing 
stress. The absence of dystrophin compromises myofiber integrity. Damaged muscle cells 
undergo degeneration and necrosis, and are eventually replaced by adipose and fibrous 
tissues. Patients gradually lose their mobility and inevitably die during early adulthood.
It has been more than two decades since the dystrophin gene mutation was recognized as the 
molecular cause of DMD. Our understanding of DMD pathogenesis remains incomplete and 
the disease remains incurable. Among many reasons that may have halted the progress is the 
shortage of appropriate animal models. While dystrophin deficiency leads to severe muscle 
atrophy and early death in humans, the characteristic clinical manifestation is not observed 
in dystrophin-null mice and cats (6–8). In contrast, dystrophin-deficient dogs show signs 
that are generally consistent with those of human patients (9).
Duchenne-like muscular dystrophy has been reported in at least 15 different dog breeds 
including beagle (10, 11), Belgian groenendaeler shepherd (12), Brittany spaniel (13), 
Cavalier King Charles spaniel (14), German short-haired pointer (15), golden retriever (11, 
16, 17), grand basset griffon vendeen (18), Irish terrier (19), Japanese spitz (20), labrador 
retriever (21), miniature schnauzer (22), old English sheepdog (23), rat terrier (24), samoyed 
(25) and weimaraner (26). However, a majority of studies have been limited to descriptive 
clinical presentations. In most cases, the disease causing mutations are not identified and 
research colonies have not been established. Nearly all our current knowledge of canine 
DMD derives from the golden retriever muscular dystrophy (GRMD) dog, a model caused 
by a single point mutation in the dystrophin gene (11, 16, 17).
A wide variety of dystrophin gene mutations have been found in human patients (27–29). 
These include deletions, insertions, duplications, and point mutations. While most in-frame 
mutations result in mild Becker muscular dystrophy (BMD) and most out-of-frame 
mutations lead to DMD, a significant number of patients do not fit into the reading-frame 
rule. Recent studies further suggest the existence of genetic modifiers that may substantially 
alter the clinical phenotype (30). Collectively, the pathogenic process of DMD is much more 
complex than we may have appreciated previously. A thorough understanding of DMD 
pathogenesis requires comprehensive analysis in multiple models. Considering the genetic 
and clinical similarities between affected dogs and human patients, establishing additional 
canine models will be extremely helpful.
Here we report a novel DMD dog model originally derived from a spontaneous mutation in 
the Pembroke Welsh corgi breed (abbreviated as “corgi” in this manuscript). The affected 
dogs showed clinical and histological changes resembling human DMD. 
Immunofluorescence staining revealed a lack of sarcolemmal dystrophin staining. We also 
identified the mutation as a long interspersed repetitive element-1 (LINE-1) insertion in 
intron 13. Similar mutations have been observed in human patients (31–38). Most 
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importantly, we have successfully established a research colony. The corgi model described 




The initial affected dog was evaluated at the College of Veterinary Medicine at Oklahoma 
State University (39). Muscle was sent to Auburn University for immunohistochemisty to 
confirm that dystrophin was deficient (Supplementary Figure 1). A small colony was 
established at Oklahoma State and subsequently sent to the University of Missouri. In 
establishing the colony at Oklahoma State, the original dogs were outbred to 
nonchondysplastic breeds. Some dogs were then provided to Auburn University to establish 
a colony. While at Auburn University, the colony has also been outbred to beagles. Thus, the 
current colony includes only mixed-breed dogs. To our knowledge, the Auburn colony is 
now the only source of affected dogs. All experimental dogs used in this study were 
produced by in-house breeding at Auburn University. All animal experiments were 
approved by the Animal Care and Use Committees of the three universities and were in 
accordance with NIH guidelines.
Histopathology studies
Tissues from four normal dogs, three affected dogs and two carriers were used in 
histopathology studies (Supplementary Table 1). Haematoxylin and eosin (HE) staining was 
used to reveal general histopathological lesions. The percentage of centrally nucleated 
myofibers were quantified in HE stained muscle cross-sections as we described before (40). 
The minimum myofiber diameter was determined from the digitized images with the Image 
J software (version 1.36b, NIH). Three random fields were analyzed for each muscle 
section. Three different sections were studied for each muscle sample. Fibrosis and muscle 
calcification were evaluated with Masson trichrome staining and Alizarin red staining, 
respectively, according to our published protocols (41). Macrophage infiltration was 
evaluated by non-specific esterase (α-naphthyl butyrate esterase) staining according to a 
published protocol (42, 43). Macrophages are dark brown cells scatted between myofibers.
Immunohistochemical staining for inflammatory cells
Immune cells were detected with the Vectastain ABC kit (Vector Laboratories, Burlingame, 
CA) according to a previously published protocol (44). Canine specific antibodies were 
obtained from AbD Serotec (Raleigh, NC). The antibody dilutions are 1:500, 1:1000, 1:200, 
1:8000 and 1:2000 for B cell, CD4+ T cell, CD8+ T cell, neutrophil and macrophage, 
respectively (44).
Immunofluorescence staining for dystrophin, utrophin and the dystrophin-associated 
glycoprotein complex (DGC)
Dystrophin was examined with ten epitope-specific antibodies including a rabbit polyclonal 
antibody against spectrin-like repeats 4–6 (1:400; Santa Cruz, CA), a mouse monoclonal 
antibody against spectrin-like repeats 6–8 (Dys-1, Novocastra, Newcastle, UK), a mouse 
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monoclonal antibody against spectrin-like repeat 11 (Mandys8, 1:200; Sigma, St Louis, 
MO), a mouse monoclonal antibody against spectrin-like repeat 10/11 (Mandys1=DD414, 
1:10; a gift from Dr. Glenn Morris, The Robert Jones and Agnes Hunt Orthopaedic Hospital, 
UK) (45), a mouse monoclonal antibody against spectrin-like repeat 14 
(Mandys110=DD417, 1:10; a gift from Dr. Glenn Morris) (45), a mouse monoclonal 
antibody against spectrin-like repeat 15 (Mandys101=DD#419, 1:10; a gift from Dr. Glenn 
Morris) (45), a mouse monoclonal antibody against spectrin-like repeat 17 (Manex44A, 
1:300; a gift from Dr. Glenn Morris) (45), a mouse monoclonal antibody against spectrin-
like repeat 14–18 (Mandys105, 1:10; a gift from Dr. Glenn Morris) (45), a mouse 
monoclonal antibody against hinge 3 (Manex50, 1:2000; a gift from Dr. Glenn Morris) (45), 
and a mouse monoclonal antibody against the C-terminal domain (Dys-2, 1:30; Novocastra). 
Utrophin was examined with a mouse monoclonal antibody against the utrophin N-terminal 
domain (VP-U579, 1:20; Vector Laboratories, Burlingame, CA). nNOS was detected with a 
polyclonal antibody (1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA). β-dystroglycan 
was revealed with a mouse monoclonal antibody (NCL-b-DG, 1:50; Novocastra). β-
sarcoglycan was revealed with a mouse monoclonal antibody (NCL-b-SARC, 1:50; 
Novocastra). Syntrophin was revealed with a pan-syntrophin mouse monoclonal antibody 
that recognizes the syntrophin PDZ domain (ab11425, 1:200; Abcam, Cambridge, MA). 
Dystrobrevin was revealed with a mouse monoclonal antibody (#610766, 1:200; BD 
Biosciences, San Diego, CA). Immunostaining was performed essentially as we described 
before (42, 46, 47).
Western blot
A ~3 mm3 piece of muscle was pulverized in liquid nitrogen in a homogenization buffer 
containing 62.5 mM Tris-HCl pH 6.8, 5 mM ethylenediaminetetraacetic acid (EDTA), 10% 
sodium dodecyl sulfate (SDS) and 1% protease inhibitor (Roche, IN). After boiling for 2 
min, the homogenate was spun at 14,000 rpm for 2 min (Eppendorf centrifuge, model 
5417C). The supernatant was used for western blots. Protein concentration was determined 
using a DC protein assay kit (Bio-Rad, Hercules, CA). 50 μg muscle lysate was 
electrophoresed on a 6% SDS-polyacrylamide gel. Protein was transferred to a nitrocellulose 
membrane. Dystrophin was detected with a monoclonal antibody against the N-terminus of 
the dystrophin protein (MANEX1A, 4C7, 1:500; a gift from Dr. Glenn Morris) (45). As a 
loading control, membrane was also probed with an anti-α-actin antibody (1:3,000; Sigma, 
St Louis, MO).
PCR genotyping
Samples of umbilical cord (5 mm long) from a newborn puppy were lysed at 95°C in a 
buffer containing 25 mM NaOH and 0.2 mM EDTA. After neutralization with 40 mM Tris-
HCl, the sample was centrifuged at 14,000 rpm for 2 min. The supernatant was collected as 
genomic DNA and used in PCR. Three PCR primers were used together in the PCR 
reaction. These include (1) a common forward primer corresponding to the dystrophin intron 
13 sequence prior to the LINE element insertion (DL1255, 5’ 
TGTCATTTCCTCAGGTTACTGCTT), (2) a reverse primer specific to the inserted LINE 
element (DL1257, 5’ TGAAGCAAATGGTGGGTATTTG), and (3) a reverse primer 
corresponding to the dystrophin intron 13 sequence after the LINE element insertion 
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(DL1256, 5’ GCAATGGCCTATCAGTACAGTCC) (Figure 5A). The PCR conditions are 
(1) 95°C for 2 min, (2) 30 cycles of 98°C for 10 sec, 60°C for 20 sec and (3) 72°C for 2 min. 
The normal allele yields a 286 bp band and the affected allele yields a 166 bp band.
Serum creatine kinase (CK) assay
Fresh serum was collected from the jugular vein. The CK level was determined with a CK 
liqui-UV test kit from Stanbio Laboratory (Boerne, TX).
Statistical analysis
Data are presented as mean ± standard error of mean. Statistical analysis was performed 
with the SPSS software (SPSS, Chicago, IL). Statistical significance for multiple group 
comparison was determined by one-way ANOVA followed by Bonferroni post hoc analysis. 
Statistical significance for two-group comparison was determined by t test. Statistical 
significance for growth curve and breeding data was analyzed with the SAS software (SAS 
Institute, Cary, NC) using the general linear model and one-side test, respectively. 
Difference was considered significant when P < 0.05.
Results
Affected corgi dogs show clinical features of muscular dystrophy
Signs of muscular dystrophy were observed in affected dogs. Compared to age-matched 
normal corgis, affected dogs showed feeding difficulties, delayed growth, generalized 
muscle wasting, short-stride shuffling and stiff gait, drooling, easy fatigability and exercise 
intolerance (Supplementary video 1). Muscle atrophy was clearly visible in the head, body 
and limb muscles (Figure 1). The tibio-tarsal jointswere “dropped” to a plantigrade position 
(Figure 1). Some affected dogs were barely able to support themselves on their paws and 
had difficulty walking.
Dystrophin is absent in affected corgi dogs
To determine the cause of muscular dystrophy in the corgi breed, we performed 
comprehensive immunofluorescence staining using antibodies that recognize dystrophin, 
utrophin, and different components of the DGC. Ten dystrophin antibodies were used in the 
study.
They recognize spectrin-like repeats 4–6, 6–8, 10/11, 11, 14, 15, 17, 14–18, hinge 3 and the 
C-terminal domain (Figure 2 and Supplementary Figure 1, data not shown for spectrin-like 
repeat 14 antibody). All of them reacted with canine dystrophin in normal dog muscle 
(Figure 2a). In affected dogs, dystrophin staining was lost at the sarcolemma (Figure 2b). 
Occasionally, revertant fibers were observed (Supplementary Figure 1). While utrophin was 
not detected in normal muscle, it was clearly visible at the sarcolemma in affected dogs 
(Figure 2). Compared to that of normal dog muscle, the β-dystroglycan, β-sarcoglycan, 
dystrobrevin and syntrophin levels were substantially reduced but not eliminated in affected 
dog muscle. nNOS was not detected at the sarcolemma in affected dogs (Figure 2b). In 
summary, the immunostaining profile suggests a diagnosis of Duchenne-like muscular 
dystrophy.
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Affected dogs display prominent muscle histopathologic lesions
On HE staining, normal corgi skeletal muscle showed minimal variation in fiber size, 
peripheral nuclei and absence of mononuclear cell infiltration. Dystrophic corgi skeletal 
muscle contained abnormally large and small fibers, prominent inflammatory cell infiltration 
and a high frequency of centrally nucleated myofibers (Figure 3a). On Masson trichrome 
staining, we observed extensive endomysial and perimysial fibrosis in affected dog muscle. 
While calcium overloading was not detected in normal muscle, highly calcified myofibers 
were frequently seen in dystrophic muscle (Figure 3a, arrowhead). Furthermore, Alizarin red 
staining revealed an elevated interstitial calcium level in affected dog muscle (Figure 3a, 
asterisk). Using non-specific esterase staining, we also detected conspicuous macrophage 
infiltration (Figure 3a, arrow).
Similar histology studies were performed on muscle samples obtained from carrier dogs. 
Despite the lack of fiber size variation, fibrosis and calcification, carrier muscles contained 
perceptible levels of centrally nucleated myofibers (Figure 3b, arrowhead) and focal 
macrophage infiltration (Figure 3b, arrow).
On quantification, ~ 0.2 % of normal muscle contained centrally located nuclei. This 
number increased to ~ 4 % and 23 % in carrier and affected muscles, respectively (Figure 
3c). Myofiber size quantification revealed a much broader distribution in affected dogs 
(Figure 3d). In normal muscle, 60 % myofibers had a minimum diameter between 32 to 40 
μm. In affected muscle, only 40 % were in this range (Figure 3d).
Cardiomyopathy is a salient feature in DMD. We examined heart histopathology of a 16-m-
old dystrophic corgi dog (Figure 3e). We observed patches of cardiomyocytes with large 
empty space in the cytoplasm resembling vacuolar degeneration (Figure 3e, arrow). In the 
same region, there was also fibrosis and calcification (Figure 3e).
Macrophages and neutrophils are the primary inflammatory cells in dystrophic corgi 
muscle
Canine specific immune cell antibodies were used to characterize inflammation (Figure 4a). 
Similar to normal muscle controls, B cell, CD4+ and CD8+ T cells were rarely detected in 
affected dog muscles (Figure 4b, data not shown for the diaphragm and the heart). 
Neutrophils and macrophages were the dominant immune cells in dystrophic muscles. In 
limb muscles and the diaphragm of affected dogs, scattered neutrophils and large aggregates 
of macrophages were observed (Figure 4c). In carrier dog limb muscles, neutrophils and 
macrophages were also detected occasionally (Figure 4d).
Neutrophil and macrophage infiltration showed a slightly different pattern in the heart. In 
the normal heart, residential neutrophils and macrophages were seen (Figure 4e) 
(neutrophils and macrophages were essentially not detected in normal skeletal muscle, data 
not shown). In dystrophic dog heart , both neutrophils and macrophages appeared as large 
aggregates spread out through out the entire heart section (Figure 4e).
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A LINE-1 element insertion aborts dystrophin expression in dystrophic corgi dogs
To identify the mutation in the affected corgi dogs, we designed primers covering the entire 
canine dystrophin cDNA and sequenced the cDNA extracted from affected dogs. We noted 
a 167 bp insertion between exons 13 and 14 (Figure 5). The insert contained an in-frame 
stop codon (TAG). A BLAST search identified the insert as part of a canine LINE-1 element 
(GenBank AB012217, 99% similarity).
To determine the location of the LINE element insertion in the canine dystrophin gene, we 
initially performed PCR using primers specific to the inserted sequence and the adjacent 
exons. Unfortunately, we were not able to get definitive PCR products suggesting that the 
insertion was not adjacent to an exon. Additional PCR primers were designed according to 
the canine genome data to entirely cover canine dystrophin intron 13 (approximately 25,000 
bp). Endogenous splicing acceptor and donor signals were intact in intron 13. A LINE-1 
element insertion was identified beginning 1,048 bp into intron 13 and spanning 
approximately 480 bp. The insertion began immediately after “cag”, a cryptic splicing 
acceptor signal in canine intron 13 (Figure 5b, Supplementary Figure 2). A conserved 
splicing donor signal “gtaagt” appeared after the first 167 bp of the insertion. The LINE-1 
element insertion ended after approximately 312 additional base pairs. The distal end of the 
insertion contained a poly A tract which has been difficult to sequence precisely. Hence, the 
total length of the insertion remained approximate.
Establishment of a dystrophic corgi colony
In an effort to utilize the corgi model for preclinical studies, we established a colony and 
characterized dogs in the colony (Figure 6, Tables 1 and 2). We first developed a PCR 
genotyping protocol (Figure 6a-c). A pair of primers specific to dystrophin intron 13 and an 
additional reverse primer specific to the insert were used in the PCR reaction. The wild type 
allele is expected to yield a 286 bp band and the mutant allele to yield two bands of 166 bp 
and ~ 766 bp. With optimized PCR conditions, only the 166 bp band, derived from the 
insertion, was detected as the diagnostic band for the affected allele (Figure 6c).
Next, we compared the breeding profile (Table 1). Two rounds of normal mating yielded 
~5.5 puppies per litter. Five puppies were male and six were female. None died during the 
first 45 days (the end of observation). Breeding carrier females with a normal male yielded 
an average litter size of ~ 5.2 puppies per litter with approximately equal numbers of males 
and females. 58% of offspring from carrier breeding were normal puppies (Table 1). This is 
slightly higher than the expected 50%. Carrier offspring accounted for about 23% puppies, 
slightly lower than the expected 25%. Sixteen percent puppies were affected. Although this 
appears lower than the expected 25%, it is not statistically significant (p = 0.2278). Seven 
cases of neonatal death were observed from six rounds of carrier breeding. Six deaths 
occurred during the first two rounds of breeding. They included three wild type puppies, two 
affected puppies and one carrier (Table 1). Among these, four puppies were stillborn.
Western blot and immunofluorescence staining were performed on muscles obtained from 
stillborn puppies. On western blot, full-length dystrophin was not detected in limb muscles 
obtained from the affected puppy. Compared to that of the normal puppy, dystrophin level 
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was apparently reduced in the carrier (Figure 6d). On immunofluorescence staining, we 
observed strong uniform dystrophin expression in skeletal muscle and the heart in the 
normal puppy. Dystrophin was not detected in an affected puppy. In skeletal muscle of a 
carrier puppy, dystrophin staining was much weaker. The signal became easily visible after 
prolonged exposure (Figure 6e top middle panel, insert). In the heart of the carrier puppy we 
found mosaic expression consisting of broad dystrophin positive regions adjacent to large 
dystrophin negative regions (Figure 6e bottom middle panel).
We also compared the serum CK levels in newborn puppies (Figure 6f). The average CK 
level in carrier puppies was about twice that of normal puppies. However, it did not reach 
statistical significance. As expected, the affected puppies had a significantly higher serum 
CK level. Nevertheless, caution should be taken when using the CK level for diagnosis. The 
lowest CK in affected puppies was 9,670 unit/liter. This is approaching the highest value in 
carriers (8,609 unit/liter) and normal (6,719 unit/liter) puppies. At 1 month of age, the serum 
CK level dropped to the baseline in normal puppies (361 ± 66 unit/liter) while it remained 
elevated in affected puppies (19,773 ± 7,754 unit/liter).
We also analyzed the growth curve (Figure 6g and h, Table 2). While the average birth body 
weights of affected males and carriers were similar to those of normal males and normal 
females, respectively, a dramatic difference in the growth rate was noted in the first 5 days 
(Table 2). Normal male puppies grew at an average rate of 34.4 g/day, while the average 
growth rate of affected male puppies was less than one-third of normal. A similar trend was 
seen in female puppies. The growth rate of a normal female was ~2.4-fold higher than that 
of a carrier. From day 6 to day 20, a higher growth rate was still noted in normal puppies but 
the relative difference to that of affected and carrier puppies became smaller. From day 21 to 
day 45, affected males continued to show a slower growth rate compared to that of normal 
male. Interestingly, the growth rate of carrier puppies was increased. Overall, the growth 
curve of normal males was significantly different from that of affected males (Figure 6G, p 
< 0.0001). The growth curve of normal females was also significantly different from that of 
carrier females (Figure 6H, p < 0.0001). Nevertheless, by the age of 45 days, growth delay 
was apparent only in affected males as the body weight of carriers had now caught up with 
that of normal female dogs.
Discussion
DMD has been a great therapeutic challenge for modern medicine. The discovery of the 
dystrophin gene in the 1980s has sparked more than two decades of intense research. Yet, a 
cure remains distant. Over the years, investigators have turned to dystrophin-deficient mdx 
mice as the primary workhorse to study disease pathogenesis and to develop therapy. 
Intermediate animal models with a body size between mice and humans may provide critical 
insights into translational research in DMD. Here, we described a symptomatic canine DMD 
model in the corgi breed. We identified the gene mutation, characterized histopathology and 
most importantly, established a research colony.
Among many mutations reported in human DMD patients, transposon-like repetitive 
element insertion constitutes a unique category. Transposons are mobile elements in the 
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eukaryotic genomes and they represent a major source of genomic diversity (48). Their 
insertion has been frequently observed in the human dystrophin gene. Specifically, 
insertions have been found in intron 2 (31), intron 7 (32), intron 11 (33, 34), intron 43 (35), 
exon 44 (36, 37) and exon 48 (38). While the insertion in intron 2 appears to be a 
polymorphic change, all other reported insertions result in clinical disease. In general, the 
inserted repetitive sequences disrupt normal dystrophin splicing. This either leads to 
pathological exon skipping or formation of a new exon containing an in-frame stop codon 
(33, 34, 36–38). In affected corgi dogs, we detected a LINE-1 element in intron 13. It 
contained the expected polyA tract and in-frame premature stop codon but not target site 
duplication (49) (Figure 5, Supplementary Figure 2). Based on genomic and cDNA 
sequence analysis, we postulate that the LINE-1 element insertion activated a cryptic 
splicing signal in intron 13. The first 167 nucleotides of the inserted LINE-1 sequence were 
spliced into the mature mRNA. Dystrophin translation is truncated by the nonsense codon in 
the LINE-1 element (Figure 5, Supplementary Figure 2).
To establish the corgi model for translational study, we characterized dystrophin, utrophin 
and DGC expression, histopathology (general morphology, fibrosis and calcification) and 
inflammation (B cell, T cell, neutrophil and macrophage) (Figures 2 to 4, Supplementary 
Figure 1). Besides rare revertant fibers (Supplementary Figure 1), dystrophin was absent 
from the sarcolemma. As a consequence of utrophin up-regulation, we detected low-level 
expression of several DGC components (Figure 2). In contrast to dystrophin, utrophin 
cannot restore nNOS to the sarcolemma (50). We did not see nNOS at the membrane 
(Figure 2).
Dystrophic muscle histopathology has been noticed in all dystrophin-deficient dogs 
irrespective of the breed. In a 2-year-old affected weimaraner, Baltzer et al. showed 
endomysial fibrosis in the diaphragm and extremely high central nucleation (~ 90%) in the 
infraspinatus msucle (26). In a 10-mold affected rat terrier, Wetterman et al. found 
pronounced fiber size variation, moderate central nucleation (~15%) but no calcium 
deposition in limb muscles (24). In a 3-m-old affected old English sheepdog, Wieczorek et 
al. reported focal degeneration and apparent myofiber calcification in the cranial tibialis 
muscle (23). In three affected Cavalier King Charles spaniels (6 to 10-m-old), Walmsley et 
al. found fiber size variation, multifocal necrosis and small basophilic regenerated fibers in 
several limb muscles (14). However, muscle calcification was rarely observed (14). In seven 
affected Japanese spitz dogs (4 to 12-month-old), Jones et al. showed segmental muscle 
necrosis, frequent calcification and occasional regeneration (~3% central nucleation) from 
multiple muscles collected at the necropsy (20). In a 3.5-m-old affected labrador retriever, 
Bergman et al. noticed myofiber size variation, some fibrosis, necrosis, regeneration and 
numerous calcific deposits in the vastus lateralis muscle (21). Klarenbeek et al. examined 
multiple muscles from three ~2-m-old affected grand basset griffon vendeen dogs. The 
histological lesions were multifocal and included fiber size variation, clusters of small 
basophilic regenerative fibers, and occasional necrosis and mineralization (18). Presthus and 
Nordstoga reported fiber size difference, hyaline degeneration and macrophage infiltration 
in three 12-week-old affected Samoyed dogs (25). In a 7-m-old affected miniature 
schnauzer, Paola et al. found small foci of inflammatory cell infiltration and myofiber 
calcification in the gastrocnemius muscle (22). In a 7-m-old affected Brittany spaniel, van 
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Ham et al. observed fiber size variation, focal lymphocyte infiltration, endomysial fibrosis 
and calcification (13). They also found increased fatty deposition in muscle tissues obtained 
from necropsy (13). van Ham et al. also studied three 5-m-old affected Belgian 
groenendaeler shepherds and found fiber size variation, hyaline degeneration, 
hypercontraction, and centrally nucleated regenerative fiber (12). We performed necropsy in 
three affected dogs that were 1.8-, 8.7- and 16-m-old (Supplementary Table 1). We observed 
a high level of central nucleation (~23%), extensive fibrosis, calcification and fiber size 
variation in skeletal muscle (Figure 3) (17, 51–54). Recently, Urasawa et al. showed 
selective vacuolar degeneration in the hearts of dystrophin-deficient beagles (52). We also 
observed vacuolar degeneration in the heart of a 16-m-old affected corgi dog (Figure 3).
Cozzi et al. examined the types of inflammatory cells in dystrophic muscle in the GRMD 
model (51). They found that ~65% of infiltrated mononuclear cells were macrophages. 
Remaining were CD4 positive (~15%) and CD8 positive (~16%) T cells. In affected corgis, 
macrophages and neutrophils were the predominant infiltrates. Surprisingly, T cells were 
rarely observed (Figure 4).
Consistent with a previous study in GRMD dogs (51), we also noted mild myopathy in corgi 
carrier muscle (Figures 3B and 4B). Heterogeneous dystrophin expression may explain this 
observation. In fact, Cooper et al have demonstrated mosaic dystrophin expression in both 
skeletal muscle and the heart in GRMD carriers (55). We also found mosaic dystrophin 
expression in newborn carrier heart. However, in newborn carrier skeletal muscle, we did 
not see large areas of dystrophin negative fibers (Figure 6e). While we cannot exclude non-
uniform expression in individual myofibers in carrier skeletal muscle, our results (western 
blot and immunostaining) clearly demonstrated a reduced dystrophin expression in corgi 
carrier skeletal muscle (Figure 6d, e).
There is no doubt that an important accomplishment of our study is the establishment of a 
corgi DMD colony. In this regard, we have developed a robust genotyping protocol (Figure 
6B). Breeding with female carriers did not alter the litter size and sex ratio. The number of 
affected puppies appeared lower than expected but it did not reach statistical significance 
(Table 1).
Neonatal death has been reported in approximately one-third to nearly half of affected 
puppies in the beagle and golden retriever background (10, 11, 56). Except for the first two 
rounds of breeding, we have not observed significant death in our colony. Since we only 
have a relatively small sample size, additional studies are needed to determine whether the 
corgi model shows a different neonatal mortality.
An intriguing question revolves around the timing of visible clinical signs of the disease. 
The high CK level suggests the presence of the disease at birth (Figure 6f). There is also 
anecdotal evidence suggesting a weaker suckling ability of affected puppies. However, 
controversy exists as to whether there is a significant growth delay at an early age. From 
weekly body weight data, Valentine et al. concluded that affected puppies had a significantly 
low body weight in the first two weeks and the trend persisted until 8 weeks of age (the end 
of the study) (11). Kornegay et al. detected a lower body weight in GRMD dogs at three 
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months of age and the growth delay persisted up to one year (57). Interestingly, a recent 
study by Shimatsu et al. showed no body weight difference between normal and affected 
male dogs from birth to 6 months of age (10). We analyzed daily body weight change in the 
corgi colony (Figure 6g, h; Table 2). Interestingly, the greatest growth rate difference was 
found in the first 5 days. During this period, we provided supplemental nutrition support to 
all puppies ad libitum. However, the growth rates of normal males and females were 3.4-
fold and 2.4-fold higher than these of affected males and carrier females, respectively (Table 
2). Our results suggest that the absence of dystrophin (affected dogs) or reduced dystrophin 
expression (carriers) may influence early growth. Since we only analyzed body weight in 3 
affected males and 5 carrier females, future studies are needed to determine whether growth 
retardation represents an early clinical sign.
Unlike golden retrievers, corgi is a chondrodysplastic (short-legged) breed. A recent study 
suggested that the stunted legs are associated with atypical expression of fibroblast growth 
factor 4 (FGF4) from a retrogene (58). Several members of the FGF family have been 
implicated in myogenesis (59, 60). Interestingly, FGF2 expression is increased in DMD 
patients (61, 62). Since the colony has been outbred, it now consists of a mixture of 
chondrodysplastic and non-chondroplastic dogs. To date, no difference in the disease 
process has been noted. Nevertheless, the sample size remains small for each category 
(chondrodysplastic or non-chondroplastic). Future comparative studies between these two 
categories may offer critical insight on whether (and how) FGF4 up-regulation may 
influence the DMD phenotype.
Large animal models hold the key in translational biomedical research. The successful 
establishment of the corgi model provides important alternatives to the current models. The 
vast majority of current DMD models are due to point mutations in the dystrophin gene. The 
corgi model reported here represents the first insertion mutation model. Comparative studies 
between the corgi model and other existing models will offer new insight on how the genetic 
background and dystrophin mutation influence disease progression and therapeutic outcome.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clinical manifestation of corgi muscular dystrophy
Representative photographs of 10-m-old corgi in standing position. Top, Rachel, a normal 
corgi. Bottom, Jerry, a dystrophic corgi. Asterisk indicates proximal limb muscle; Cross 
indicated distal limb muscle; Arrow indicates the tibial-tarsal joint. The affected dog Jerry 
shows limb atrophy and his tibial-tarsal joints are dropped to the ground.
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Figure 2. Characterization of dystrophin, utrophin and dystrophin-associated protein expression 
in normal and affected dog skeletal muscle by immunofluorescence staining
Immunofluorescence staining was performed on serial muscle sections with antibodies 
specific for dystrophin N-terminal domain, dystrophin spectrin-like repeats R4–6, R6–8, 
R11 and R17, dystrophin hinge 3 (H3) and dystrophin C-terminal domain, utrophin, β-
dystroglycan, β-sarcoglycan, dystrobrevin and syntrophin. a, Representative 
immunofluorescence images from skeletal muscle of a normal corgi dog. b, Representative 
immunofluorescence images from skeletal muscle of a dystrophic corgi dog. Scale bar 
applies to all the images in the same panel.
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Figure 3. Characterization of muscle histopathology in carrier and dystrophic corgi dogs
a, Representative images of HE, Masson trichrome (for fibrosis), Alizarin red (for calcium) 
and non-specific esterase (for macrophages) staining of serial muscle sections from normal 
limb muscle, dystrophic limb muscle and the dystrophic diaphragm. High magnification 
images of the boxed areas are shown for Masson trichrome and non-specific esterase 
staining. Arrowhead, individual myofiber with strong calcium staining; Asterisk, enhanced 
interstitial calcium staining in dystrophic muscle; Arrow, macrophages. b, Representative 
images of HE, Alizarin red, Masson trichrome and non-specific esterase staining from limb 
muscle of a carrier dog. High magnification images of the boxed areas are shown for 
Masson trichrome and non-specific esterase staining. Arrowhead, centrally localized nuclei; 
White arrow, focal inflammation; Black arrow, macrophages. c, Quantification of central 
nucleation from the limb muscle of normal, carrier and affected dogs. Asterisk, significantly 
different from the other groups. Black bar, normal (N = 1,259 fibers); gray bar, carrier (N = 
875 fibers); white bar, affected (N = 1,553 fibers). d, Histograms of minimum myofiber 
diameter from normal (black bars, N = 394 fibers) and affected (white bars, N = 310 fibers) 
dog limb muscle. e, Representative HE, Masson trichrome and Alizarin red stained images 
from the heart of normal and affected dogs. High power HE stained images correspond to 
the boxed areas in each row. Arrow, vacuolar degeneration seen only in dystrophic heart. 
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Please note, the Masson trichrome positive area in the normal heart corresponds to vessel 
location.
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Figure 4. Characterization of immune cell infiltration in the limb muscle, diaphragm and the 
heart
a, Representative photomicrographs of immunohistostaining in the dog spleen. For CD8+ T 
cell and the secondary antibody alone, high power images of the boxed areas are shown. 
Positive cells stain in dark purple color. b, Representative photomicrographs of 
immunohistostaining for B cells, CD4+ T cells and CD8+ T cells in the limb muscle of 
dystrophic corgi dogs. Yellow arrowhead, a rare B cell. c, photomicrographs of 
immunohistostaining for neutrophils and macrophages in the limb muscle and diaphragm of 
dystrophic corgi dogs. Top panel, low magnification images; Bottom panel, high 
magnification images. Purple arrowhead, neutrophil in dystrophic limb muscle; Green 
arrowhead, neutrophil in dystrophic diaphragm muscle. Neutrophils are less abundant than 
macrophages. d, Representative photomicrographs of immunohistostaining for neutrophils 
and macrophages in the limb muscle of normal and carrier dogs. Arrow, centrally located 
nuclei; Blue arrowhead, a neutrophil in the carrier limb muscle; Red arrowhead, a 
macrophage in the carrier limb muscle. e, photomicrographs of immunohistostaining for 
neutrophils and macrophages in the heart of normal and dystrophic corgi dogs. Top panel, 
low magnification images; Bottom panel, high magnification images. Left two columns, 
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normal heart; Right two columns, dystrophic heart. Pink arrowhead, sporadic neutrophil in 
the normal heart; Orange arrowhead, sporadic macrophage in the normal heart; Scale bar 
applies to all the images in the same row.
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Figure 5. Mutation in the corgi model
a, Schematic outline of the normal canine dystrophin gene, mRNA and protein between 
exons 13 and 14. b, Schematic outline of the mutation in affected corgi. Gray letters, from 
normal canine dystrophin; Black letters, from LINE element insertion; Small letters, 
nucleotides in intron; Bolded small letters, conserved splicing signal in intron; Capital 
letters, nucleotides in exon; Bolded capital letters, stop codon. The cartoons are not drawn to 
scale.
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Figure 6. Establishment of a corgi muscular dystrophy colony
a, Schematic representation of the genotyping PCR primer location and expected PCR 
product size from the normal allele. Arrows, the location of the PCR primers used for 
genotyping. DL1255 is the common forward primer. DL1256 is a reverse primer 
corresponding to a region distal of the inserted LINE-1 element in dystrophin intron 13. The 
normal allele results in a 286 bp PCR product. b, Schematic representation of the 
genotyping PCR primer location and expected PCR product size from the affected allele. A 
canine repetitive element LINE-1 (gray color) is inserted in intron 13. The insertion 
introduces a pair of splicing signals (SA, splicing acceptor; SD, splicing donor). A new exon 
is created and it contains an in-frame stop codon (asterisk). Arrows, the location of the PCR 
primers used for genotyping. DL1257 is the mutation specific reverse primer. The mutated 
allele is expected to yield a 167 bp and a ~766 bp PCR product. c, PCR genotyping results 
from a litter. Optimized PCR condition allows for the amplification of the 167 bp band only 
from the affected allele. Two are normal puppies, one is an affected puppy and one is a 
carrier. The last lane represents the negative water control in which no DNA template was 
added in the reaction. d, Representative whole muscle lysate western blot from limb muscles 
of normal, carrier and affected puppies. α-Actin is the loading control. e, Representative 
dystrophin immunofluorescence staining images from neonatal puppies. Top panels, skeletal 
muscle. Under the same exposure condition, staining is much weaker in carrier puppy 
skeletal muscle. Right corner inset in the carrier puppy panel is a longer exposure 
photomicrograph of the boxed area. Bottom panels, heart. Asterisk, a dystrophin negative 
region in the carrier puppy heart. f, Serum CK quantification from newborn puppy and 1-
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month-old dog. Sample sizes for normal newborn male, affected newborn male, normal 
newborn female, carrier newborn female, normal 1-m-old male and affected 1-m-old male 
are 8, 3, 12, 3, 4 and 3, respectively. Asterisk, significantly different from other groups in 
the same panel. g, Growth curve of normal and affected male puppies. Trend lines and 
sample size are indicated. h, Growth curve of normal and carrier female puppies. Trend lines 
and sample size are shown.
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Table 1
Breeding record
Parent Information Male Normal Femalea Normal Male Normal Femaleb Carrier
Mating 2 6
Litter size 4, 7 2c, 3, 5, 6d, 6, 9
Average litter size 5.5 5.2
Puppy number
 Total 11 31
 Male 5 (45.5%) 14 (45.2%)
 Female 6 (54.5%) 16 (51.6%)
 Unknown gender 0 1 (3.2%)e
Puppy genotype
 Normal 11 (100%) 18 (58.1%)
 Affectedf 0 (0%) 5 (16.1%)
 Carrier 0 (0%) 7 (22.6%)
 Unknown 0 (0%) 1 (3.2%)e
Neonatal deathg
 Normal 0 3h
 Affected NA 2 (stillborn)
 Carrier NA 1 (stillborn)
Unknown genotype NA 1 (stillborn)e
a
Two females (Adrian and Madonna) were used in breeding.
b
Four female (Crash, Rachel, Monica, and Bitty) were used in breeding. Three litters were from carrier Monica.
c
This litter was born on 7/6/2007. Both puppies were female (one is normal, the other is a carrier) and both were stillborn.
d
This litter was born on 6/25/2007. Only two survived from this litter (1 normal male and 1 carrier). Two affected males were stillborn. One 
normal male died at day 3 and one normal female died at day 8.
e
This was a stillbirth and puppy’s gender was not recorded and tissue is not available for genotyping.
f
All affected are male.
g
Neonatal death also include five cases of stillbirth. Four deaths were from the first litter of carrier Rachel (see c) and two from the first litter of 
carrier Crash (see d). These deaths occurred in 2007. These two carriers were not used for breeding since then. One stillbirth occurred in later 2009 
and it was the third litter from carrier Monica. This was also the largest litter (total 9 puppies).
h
One normal male is stillborn, one normal male died at day 3 and one normal female died at day 8.
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